Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04307953Phase 2Recruiting

Saracatinib Trial TO Prevent FOP

Role: collaborator

NCT05425771Not ApplicableUnknown

ARMA (Antireflux Mucosa Ablation) in Patients With Chronic Refractory Reflux Disease

Role: lead

NCT01836900Not ApplicableUnknown

Endoscopic Treatment of Recurrent Upper GI Bleeding: OTSC [Over the Scope Clip] Versus Standard Therapy

Role: collaborator

All 3 trials loaded